Viatris Inc.
VTRS
Rankning i aktier
#1089
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its... Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Aktiekurs
$18.61
Marknadsvärde
$21.37B
Förändring (1 dag)
-0.24%
Förändring (1 år)
79.07%
Land
US
Handel Viatris Inc. (VTRS)
Kategori
Healthcare
Intäkter för Viatris Inc. (VTRS)
Intäkter i Jun 2026 TTM: $14.74B
Enligt Viatris Inc. senaste finansiella rapporter är företagets nuvarande intäkter (TTM) $14.74B. År 2023 hade företaget intäkter på $15.43B en minskning jämfört med intäkterna år 2022, som var $16.26B. Intäkter är det totala belopp som ett företag genererar från försäljning av varor eller tjänster. Till skillnad från vinst dras inga kostnader av.
Intäktshistorik för Viatris Inc. från 2004 till 2026
Intäkter vid slutet av varje år
| År | Intäkter | Ändra |
|---|---|---|
| 2026 (TTM) | $14.74B | -0.01% |
| 2024 | $14.74B | -4.46% |
| 2023 | $15.43B | -5.14% |
| 2022 | $16.26B | -9.08% |
| 2021 | $17.89B | 49.73% |
| 2020 | $11.95B | 3.87% |
| 2019 | $11.50B | 0.58% |
| 2018 | $11.43B | -3.98% |
| 2017 | $11.91B | 7.50% |
| 2016 | $11.08B | 17.47% |
| 2015 | $9.43B | 22.15% |
| 2014 | $7.72B | 11.73% |
| 2013 | $6.91B | 1.66% |
| 2012 | $6.80B | 10.87% |
| 2011 | $6.13B | 12.46% |
| 2010 | $5.45B | 7.02% |
| 2009 | $5.09B | -0.87% |
| 2008 | $5.14B | 76.85% |
| 2007 | $2.91B | 131.08% |
| 2006 | $1.26B | 0.30% |
| 2005 | $1.25B | -8.82% |
| 2004 | $1.37B | 0.00% |
Intäkter för liknande företag eller konkurrenter
| Företag | Intäkter | Intäktsdifferens | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | -55.14% |
IN
|
